To evaluate recombinant human luteinizing hormone ( r-hLH ) versus urine-derived human chorionic gonadotropin ( u-hCG ) to trigger ovulation in women ( aged 20-40 years ) with WHO Group II anovulatory infertility undergoing ovulation induction ( OI ) with recombinant human follicle-stimulating hormone ( r-hFSH ) ( 150 IU/day starting dose ) .